Genomic Profiles and Clinical Outcomes of Penile Squamous Cell Carcinoma With Elevated Tumor Mutational Burden
JAMA Network Open · 2023
DOI: 10.1001/jamanetworkopen.2023.48002 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, 2023. Verfasst von Andrea Necchi und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Penile Neoplasms. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Tumor mutational burden (TMB) is a putative biomarker of efficacy for immune checkpoint inhibitor (ICI) therapies of solid tumors, but not specifically for penile squamous cell carcinoma (PSCC).
Objective
To characterize biomarker features and ICI therapy outcomes associated with high TMB in PSCC in the routine clinical practice setting. Design, Setting, and Participants In this cohort study, 397 PSCC cases were analyzed to identify genomic alterations in more than 300 cancer-associated genes and genomic signatures, including TMB, using a hybrid capture–based comprehensive genomic profiling assay. Tumor mutational burden was categorized as low (<10 mutations per megabase [mut/Mb]), high (10-19 mut/Mb), or very high (≥20 mut/Mb). Germline status of genetic alterations was predicted using a validated somatic-germline computational method. Clinical outcomes of patients with metastatic PSCC receiving first-line ICI were abstracted using the deidentified nationwide Clinico-Genomic Database (CGDB) from January 1, 2011, through December 31, 2022. Exposure Comprehensive genomic profiling was performed using FoundationOne and FoundationOne CDx assays from Foundation Medicine Inc. Main outcomes and measures The spectrum of genetic alterations by TMB level in PSCC, the percentage of germline genetic alterations, and the outcome (overall survival with routine clinical treatment) by TMB of chemotherapy-naive patients with PSCC who received ICI treatment up front were assessed in this descriptive study.
Results
Among 397 patients (median [IQR] age, 65 [54-73] years; 266 [67.0%] of European, 83 [20.9%] of admixed American, and 34 [8.5%] of African or other genomic ancestry), the median (IQR) age (eg, 65 [53-73] years for low TMB vs 68 [61-78] years for TMB ≥10 mut/Mb) and genomic ancestry distribution (eg, European 228 of 339 [67.3%] for low TMB vs 38 of 58 [65.5%] for TMB ≥10 mut/Mb) were similar between TMB subgroups. There were 339 PSCC cases (85.4%) with low TMB, 40 cases (10.1%) with high TMB, and 18 cases (4.5%) with very high TMB. Comparisons of TMB of 10 mut/Mb or higher vs low TMB showed an enrichment of genetic alterations in PIK3CA (48.3% vs 18.3%; P < .001) and KMT2D (29.3% vs 7.7%; P < .001) and less frequent genetic alterations in CDKN2A (25.9% vs 45.7%; P = .05). Most genetic alterations did not co-occur. Human papillomavirus identification was more frequent as TMB increased: 28.3% for low TMB, 50.0% for high, and 72.2% for very high. In total, 95 of 1377 genetic alterations (6.9%) were germline. Of 10 patients identified from the CGDB receiving frontline ICIs, median (IQR) follow-up was 9.9 months. Four patients had overall survival with clinical treatment of more than 12 months, including 2 of 3 patients with TMB of 10 mut/Mb or higher. Conclusions and Relevance In this cohort study of advanced metastatic PSCC based on TMB levels, significant differences were observed for biomarkers in nearly 15% of patients with a TMB of 10 mut/Mb or higher. Germline testing and ICI-based therapy should be integrated into the management of selected PSCC cases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy.
- Vita-Salute San Raffaele University, Milan, Italy.
- Department of GU Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
- Division of Oncology, Department of Medicine, University of Washington, Seattle.
- Fred Hutchinson Cancer Center, Seattle, Washington.
- Foundation Medicine, Inc, Cambridge, Massachusetts.
Zitieren
APA
Necchi, A., Spiess, P. E., Costa de Padua, T., Li, R., Grivas, P., Huang, R. S. P., Lin, D. I., Danziger, N., Ross, J. S., Jacob, J. M., Sager, R. A., Basnet, A., Li, G., Graf, R. P., Pavlick, D. C., & Bratslavsky, G. (2023). Genomic Profiles and Clinical Outcomes of Penile Squamous Cell Carcinoma With Elevated Tumor Mutational Burden. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2023.48002
Vancouver
Necchi A, Spiess PE, Costa de Padua T, Li R, Grivas P, Huang RSP, et al. Genomic Profiles and Clinical Outcomes of Penile Squamous Cell Carcinoma With Elevated Tumor Mutational Burden. JAMA Network Open. 2023. doi:10.1001/jamanetworkopen.2023.48002
BibTeX
@article{Necchi2023,
author = {Necchi, Andrea and Spiess, Philippe E and Costa de Padua, Tiago and Li, Roger and Grivas, Petros and Huang, Richard S P and Lin, Douglas I and Danziger, Natalie and Ross, Jeffrey S and Jacob, Joseph M and Sager, Rebecca A and Basnet, Alina and Li, Gerald and Graf, Ryon P and Pavlick, Dean C and Bratslavsky, Gennady},
title = {Genomic Profiles and Clinical Outcomes of Penile Squamous Cell Carcinoma With Elevated Tumor Mutational Burden},
journal = {JAMA Network Open},
year = {2023},
doi = {10.1001/jamanetworkopen.2023.48002}
}
EUVIMED